Naslov
EXPRESSION OF CD43 IS AN IMPORTANT PROGNOSTIC FACTOR IN A DIFFUSE LARGE B-CELL LYMPHOMA

Autori
Ilić, Ivana ; Mitrović, Zdravko ; Aurer, Igor ; Basić-Kinda, Sandra ; Radman, Ivo ; Ajduković, Radmila ; Labar, Boris ; Dotlić, Snježana ; Nola, Marin

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Journal of hematopathology / J. H.J.M. van Krieken - : Springer, 2008, 221-221

Skup
XIV. Meeting of the European Association for Haematopathology

Mjesto i datum
Bordeaux, Francuska, 20.09.2008. - 25.09.2008

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
non-hodgkin lymphoma; diffuse large b-cell lymphoma; cd43; prognosis

Sažetak
Background. CD43 is a membrane protein expressed on all hematopoetic cells except resting B-cells and erythrocytes with a postulated role in adhesion, T-cell activation and apoptosis. CD43 is expressed in about 20% of diffuse large B-cell lymphoma (DLBCL) but its prognostic significance in DLBCL is still unknown. Purpose of the study. To define the prognostic significance of CD43 on DLBCL. Methods. With a use of a standard immunohistochemistry we analyzed the protein expression of CD43 and its prognostic significance in 101 patients with DLBCL consecutively collected from our archive. All patients were treated with anthracycline-based chemotherapy or with antracycline-based therapy combined with rituximab. Results. CD43 was expressed in 25/101 patients (25%). The median follow-up of survivors was 36 months (range 1-177 months). CD43+ patients had significantly lower complete response rates (56% vs. 84%, p<0.001), inferior event-free survival (EFS) (26% vs. 66% at 2 years, p<0.001) and overall survival (OS) (44% vs. 71% at 2 years, p=0.001) than CD43- patients. The prognostic impact of CD43 was not affected by rituximab treatment. CD43 expression was not related to IPI score, stage, LDH, age, performance status or GCB vs. non-GCB type as determined by immunohistochemistry. Conclusion. The expression of CD43 in patients with DLBCL identifies a subgroup of patients with significantly inferior response rates, EFS and OS. This effect is independent of the IPI score or rituximab treatment. The data presented suggest that expression of CD43 is an independent prognostic factor in DLBCL.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti

POVEZANOST RADA